{"filings":[{"id":3484957,"accession_number":"0001493152-26-047242","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-10-15T20:15:36+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics abandons annual meeting after 4 failed quorum attempts; plans special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting held September 3, 2026 lacked a quorum; reconvened September 24, September 30 and October 14, 2026 with no quorum on any date.","Company determined not to adjourn again; no business was transacted and none of the meeting's proposals were voted on.","Co-Diagnostics intends to seek stockholder approval of those proposals at a special meeting on a future, still-unannounced date.","Date, time and location of any special meeting will be disclosed in proxy materials filed with the SEC and sent to stockholders.","Signed by CEO Dwight Egan on October 15, 2026; common stock (CODX) trades on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3466197,"accession_number":"0001493152-26-047089","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K/A","filed_at":"2026-10-15T10:10:23+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Co-Diagnostics issues $2.835M J.J. Astor secured convertible note; pledges all ATM proceeds to lender","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["J.J. Astor & Co. funded a $2.1M initial loan on Oct 9, 2026; Co-Diagnostics issued a $2.835M principal note (1.35x factor rate), netting ~$2.016M after a 4% origination fee.","Optional $1.0M second tranche after 60 days comes via a $1.35M note. Notes repay in 30 weekly installments, secured by a senior lien on substantially all assets; $250K minimum cash covenant.","Conversion price is 90% of the lowest 10-day VWAP (80% after default), floored at 20% of the Nasdaq minimum price; default raises principal to 120% plus 19% default interest, compounded daily.","Issued 600,000 commitment shares; make-whole shares due if sold below $0.218. Lender capped at 9.99% beneficial ownership, raisable to 19.99% on 61 days' notice.","All ATM net proceeds route through a DACA account at East West Bank: first $1M to Astor, then 80/20 lender/company until weekly payments clear, then 25/75. Maxim gets a 5% placement fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3411638,"accession_number":"0001493152-26-046676","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-10-13T10:10:19+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Co-Diagnostics borrows up to $3.1M from J.J. Astor at 1.35x factor; issues 600,000 commitment shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $2.1M loan funded Oct 9, 2026; Initial Note principal $2,835,000 at 1.35x factor; 4% origination fee leaves about $2.016M net proceeds.","Company may borrow an extra $1.0M after 60 days via a $1.35M Additional Note; notes repay in 30 weekly installments with a $250,000 minimum cash covenant.","Conversion price is greater of 90% of 10-day low VWAP or Nasdaq Minimum Price of $1.09, floored at 20% of that; default raises principal to 120% plus 19% interest compounded daily.","600,000 commitment shares issued; make-whole shares owed if sold below $0.218; beneficial ownership cap 9.99%, raisable to 19.99%.","100% of ATM net proceeds routed to Astor-controlled account: first $1.0M to lender, then 80/20; ATM program is $7,350,877.68; Maxim earns 5% placement fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3245802,"accession_number":"0001493152-26-045652","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-10-02T23:38:44+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics annual meeting fails quorum again; adjourned to Oct. 14","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting held Sept. 3, 2026 did not achieve a quorum; adjourned sessions on Sept. 24 and Sept. 30 also failed to reach quorum.","No business was transacted at any of the three sessions; meeting adjourned again to October 14, 2026, 9:30 a.m. Mountain Time.","Reconvened meeting will be held at Co-Diagnostics' offices, 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.","Valid proxies already submitted remain valid for the reconvened meeting unless properly changed or revoked before votes are taken.","Bylaws permit the chairperson to adjourn without notice other than an announcement until a quorum is present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3100836,"accession_number":"0001493152-26-044346","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-09-25T20:45:25+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics annual meeting fails quorum twice; adjourned again to Sept 30, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting held September 3, 2026 did not achieve a quorum and could not transact business; meeting adjourned.","Adjourned meeting on September 24, 2026 also failed to reach quorum, so no shareholder votes were taken.","Meeting adjourned again to September 30, 2026 at 9:00 a.m. Mountain Time at company offices, 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah.","Valid proxies submitted earlier remain valid for the reconvened meeting unless properly changed or revoked; items are per the July 21, 2026 definitive proxy.","CEO Dwight Egan signed the report dated September 24, 2026; no voting results for any proposal were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2894036,"accession_number":"0001493152-26-042854","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-09-16T14:30:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"Co-Diagnostics hosts investor presentation on ReadyGo collaboration, Co-Dx PCR platform, India ops","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated September 16, 2026 covers collaboration with ReadyGo Diagnostics Ltd.","Topics include Co-Dx PCR platform development, manufacturing initiatives, and India operations.","No financial metrics or guidance disclosed in the 8-K body; details appear in presentation materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2890276,"accession_number":"0001493152-26-042844","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-09-16T12:45:13+00:00","items":["8.01","9.01"],"status":"ready","headline":"Co-Diagnostics, ReadyGo collaborate on blood-based PCR testing, starting with Ebola","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration to test ReadyGo's GoCollect sample-prep with Co-Dx PCR platform for blood-based molecular testing at point of need.","Initial focus on decentralized Ebola detection; WHO cites 6,757 confirmed cases, 3,267 deaths in DRC outbreak as of Sept 7, 2026.","Feasibility work underway; no compatibility established yet; Co-Dx PCR platform not FDA cleared or available for sale.","Success could expand platform to bloodborne pathogens including HIV and hepatitis B/C, representing larger markets than current swab menu."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2880118,"accession_number":"0001493152-26-042744","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-09-15T20:05:28+00:00","items":["8.01"],"status":"ready","headline":"Co-Diagnostics signs MTA with ReadyGo to test sample prep tech on Co-Dx PCR platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In August 2026, Co-Diagnostics entered a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate ReadyGo's sample collection/preparation tech.","Evaluation covers compatibility of ReadyGo's sample collection, lysis, stabilization, and prep technologies with Co-Dx PCR platform.","ReadyGo will supply sampling materials for feasibility studies; no obligation for further development, supply, or commercialization.","Co-Dx PCR platform and tests are not yet FDA-approved and are not currently available for sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2686403,"accession_number":"0001493152-26-041560","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-09-04T20:30:17+00:00","items":["5.02"],"status":"ready","headline":"Co-Diagnostics CFO Brian Brown departs; Daniel Bohrer named principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Brown's last day as CFO was Sept 2, 2026; he served as principal financial and accounting officer through that date.","Daniel Bohrer, EVP of Finance and Accounting, appointed principal financial and accounting officer effective Sept 2, 2026.","Bohrer's annual salary increased from $225,000 to $255,000 in connection with the appointment.","Bohrer has been with Co-Diagnostics since 2021 as VP then EVP; previously at Workfront and EY.","No family relationships or related-party transactions noted in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2668837,"accession_number":"0001493152-26-041468","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-09-04T13:00:15+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics annual meeting adjourned for lack of quorum; reconvened Sept 24","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sept 3, 2026 annual meeting lacked quorum; no business transacted.","Meeting adjourned to Sept 24, 2026 at 9:00 a.m. MT in Salt Lake City.","Valid proxies submitted before adjournment remain valid unless changed or revoked.","No vote results reported; items deferred to reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2243837,"accession_number":"0001493152-26-037739","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-08-13T20:03:21+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q2 net loss narrows to $6.3M; FDA 510(k) submitted for Flu/RSV test","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.17M vs $0.16M YoY; net loss $6.3M ($1.46/share) vs $7.7M ($7.00) prior year.","Operating loss $6.2M, improved from $8.1M; adjusted EBITDA loss $5.8M vs $7.2M; cash $3.6M.","Submitted FDA 510(k) for Flu A/B & RSV test on PCR Pro; clinical study 1,400+ patients, 27 analytical studies, 10,000+ runs.","Advanced Saudi manufacturing: industrial site approval and lease in Sudair Industrial City; distribution agreement in Mexico.","Appointed Wes Lindsey, Ph.D. as Chief Scientific Officer; initiated TB studies in India via CoSara."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1977759,"accession_number":"0001493152-26-035553","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-07-31T12:30:15+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Co-Diagnostics raises ~$2.67M via warrant exercise; issues new warrants for 3.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$2.67M from cash exercise of 1,702,362 existing warrants at $1.571/share.","New warrants to purchase up to 3,404,724 shares at $1.56/share, exercisable only after stockholder approval.","Outstanding shares to increase from 5,277,846 to 6,980,208 after the exercise.","Placement agent Maxim Group LLC receives 7% cash fee and $50,000 expense reimbursement.","Net proceeds to be used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1888241,"accession_number":"0001493152-26-034837","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-07-27T21:05:36+00:00","items":["1.01","9.01"],"status":"ready","headline":"Co-Diagnostics removes $10M cap on ATM equity offering with Maxim Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to equity distribution agreement removes fixed $10M aggregate limit on common stock sales.","Future sales limited only by registered shares available under effective S-3 registration statement.","Company extends standstill period with prior investors to August 14, 2026, restricting further equity issuances.","Sales will be made through Maxim Group as agent under new prospectus supplement filed July 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":564080,"accession_number":"0001493152-26-024738","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-05-21T12:00:36+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Co-Diagnostics raises $3.0M in private placement of stock and warrants at $1.821/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.0M from sale of 1.65M shares/pre-funded warrants and 3.29M common warrants.","Common warrants exercisable immediately at $1.571/share, expire in five years; pre-funded warrants at $0.0001.","Offering priced at-the-market under Nasdaq rules; expected to close May 21, 2026.","Maxim Group LLC acted as sole placement agent; net proceeds for general corporate purposes and working capital.","Company agreed to file a resale registration statement within 15 days to register the securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442526,"accession_number":"0001493152-26-023059","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-05-14T20:05:17+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.","Net loss $9.1M ($4.06/share) vs $7.5M ($7.05/share); adjusted EBITDA loss $8.7M.","Cash $8.2M at Mar 31, 2026, down from $11.9M at Dec 31, 2025.","Received CDSCO license for CoSara PCR Pro instrument in India; ISO 13485 certification for manufacturing facility.","Completed enrollment in upper respiratory test clinical study with >1,400 patients; advancing TB study in India."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":145954.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107338,"accession_number":"0001493152-26-014129","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.","Cash at $11.9M, down from $29.7M; adjusted EBITDA loss improved to $28.0M from $33.5M.","Received CDSCO license for PCR Pro instrument in India; expanding to South Asia with $13B addressable market.","Planning initial FDA 510(k) for flu A/B/RSV test, dropping COVID from initial submission to accelerate timeline.","Closed stock offerings raising $10.8M; engaged Maxim Group for potential SPAC for CoSara."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":145954.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107337,"accession_number":"0001493152-26-009478","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Co-Diagnostics regains Nasdaq compliance; preliminary cash $11.9M as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Co-Diagnostics (CODX) of compliance with $1.00 bid price rule; trading resumes March 11, 2026.","Nasdaq Hearing Panel closed; one-year Discretionary Panel Monitor imposed through March 9, 2027.","If bid price falls below $1.00 for 30 consecutive trading days, no 180-day cure period; delist determination possible.","Preliminary cash and cash equivalents estimated at $11.9M as of December 31, 2025; unaudited and subject to adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107336,"accession_number":"0001493152-26-001971","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Staff determined to delist CODX due to continued non-compliance with minimum bid price rule.","Trading on Nasdaq suspended from open on Jan 14, 2026; shares expected to trade on OTC Pink under CODX.","Company plans to request a hearing with Nasdaq Hearings Panel to address bid price deficiency.","Since Jan 2, 2026 (1-for-30 reverse split effective), bid price closed at or above $1.00; may seek compliance if 10 consecutive days ending Jan 15 show $1.00.","Prior non-compliance notice Jan 10, 2025; two compliance periods expired Jan 5, 2026 without meeting rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123696,"accession_number":"0001493152-25-029513","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics files 1-for-30 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-30; effective January 2, 2026 at 12:01 a.m. ET.","Approximately 2,095,031 shares outstanding post-split; new CUSIP 189763204; ticker CODX unchanged.","Fractional shares rounded up to next whole share; no fractional shares issued.","Split intended to enable compliance with Nasdaq $1.00 minimum bid price listing requirement.","Board approved ratio on Dec 29, 2025; stockholders authorized up to 1-for-30 at Dec 5 special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123695,"accession_number":"0001493152-25-026385","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics shareholders approve reverse stock split up to 1-for-30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting on Dec 5, 2025 approved amendment for reverse stock split.","Vote: 26,465,960 for, 4,213,378 against, 194,746 abstain – passed.","Board authorized to set final ratio between 1-for-2 and 1-for-30 within 12 months.","No other proposals were voted on at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123694,"accession_number":"0001493152-25-022283","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q3 net loss narrows to $5.9M; announces JV in Saudi Arabia and SPAC exploration for India unit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.1M, down from $0.6M YoY; net loss $5.9M ($0.16/share) vs $9.7M ($0.32) in Q3 2024.","Operating loss $7.0M vs $10.2M; adjusted EBITDA loss $6.3M.","Cash and marketable securities $11.4M at Sept 30, 2025.","Signed JV with Arabian Eagle Manufacturing for CoMira Diagnostics in KSA and 18 MENA nations.","Engaged Maxim Group to pursue SPAC transaction for CoSara India JV; closed RDOs totaling ~$10.8M gross."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":358567.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123693,"accession_number":"0001493152-25-020100","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Co-Diagnostics prices $7.0M registered direct offering of 12.7M shares at $0.55/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 12,727,272 shares of common stock or pre-funded warrants at $0.55 per share.","Pre-funded warrants have an exercise price of $0.0001 and expire when exercised in full.","Gross proceeds estimated at $7.0M before placement agent fees and expenses.","Proceeds to be used for working capital and general corporate purposes.","Maxim Group LLC is the sole placement agent; offering expected to close October 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123692,"accession_number":"0001493152-25-018591","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Co-Diagnostics enters $10M ATM equity distribution with Maxim Group, terminates prior Piper Sandler ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM allows sale of up to $10M in common stock through Maxim Group at market prices; 3.0% commission.","Prior ATM agreement with Piper Sandler and Clear Street terminated effective September 30, 2025.","Shares sold under existing effective S-3 shelf (333-270628); prospectus supplement filed Oct 20, 2025.","Company has no obligation to sell any shares; offering may be terminated at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140380,"accession_number":"0001493152-25-016211","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Co-Diagnostics to present at Lytham Partners Fall 2025 Investor Conference on Sept 30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Webcast presentation at 4:15 p.m. ET on September 30, 2025; replay available.","Management will host virtual one-on-one meetings; registration via Lytham Partners.","No financial results or material business updates disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140379,"accession_number":"0001493152-25-013981","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Co-Diagnostics announces $3.8M registered direct offering of 9.62M shares at $0.40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 9,619,000 common shares at $0.40/share in registered direct offering to institutional investors.","Gross proceeds $3.8M; net after 7% placement agent fee and expenses; use for working capital.","Maxim Group LLC is sole placement agent; closing expected Sept 18, 2025.","Investors get participation rights in up to 30% of future financings within 12 months.","Offering priced at-the-market under Nasdaq rules; customary 30-day lock-up on new issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140378,"accession_number":"0001641172-25-023968","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q2 revenue falls to $0.2M from $2.7M; net loss $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.2M vs $2.7M in Q2 2024; no grant revenue recognized in Q2 2025.","Operating loss $8.1M vs $7.7M prior year; expenses down 19.1% to $8.2M.","Net loss $7.7M ($0.23 per share) vs $7.6M ($0.25 per share) in Q2 2024.","Cash & marketable securities $13.4M as of June 30, 2025; adjusted EBITDA loss $7.2M.","On track to initiate clinical evaluations for Co-Dx PCR platform tests before year-end; enhanced COVID-19 test trial starting imminently."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":213187.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140377,"accession_number":"0001641172-25-018753","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Co-Diagnostics gets 180-day Nasdaq extension to meet $1 minimum bid rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Additional 180-day grace period to regain compliance expires January 5, 2026.","Failed to regain $1 bid compliance during initial 180-day period.","Qualifies for extension by meeting all other Nasdaq Capital Market listing requirements.","Intends to cure deficiency via reverse stock split if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158034,"accession_number":"0001641172-25-012871","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics shareholders elect all five director nominees, approve 2025 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson, and Eward Murphy each elected with >10.2M votes for.","2025 Equity Incentive Plan approved with 10,676,931 for, 2,761,398 against, 61,338 abstain.","Advisory vote on executive compensation passed with 11,042,215 for, 2,296,490 against.","Ratification of Tanner LLC as auditor for 2025 approved with 16,724,962 for, 803,028 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158033,"accession_number":"0001641172-25-009249","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.","Net loss of $7.5M ($0.24 loss per share) compared to net loss of $9.3M ($0.31 per share) in Q1 2024.","Operating loss improved to $8.6M from $10.3M YoY; operating expenses decreased 18.2%.","Cash and marketable securities totaled $21.5M as of March 31, 2025.","On track to begin clinical evaluations for 4 tests and complete India manufacturing facility by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":50277.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158032,"accession_number":"0001641172-25-006324","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Co-Diagnostics amends equity distribution agreement, adds Clear Street as sales agent, up to $17.1M remaining","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended equity distribution agreement adds Clear Street LLC as sales agent alongside Piper Sandler, effective April 25, 2025.","Aggregate offering price up to $17,111,650 remains available; Co-Diagnostics had sold 833,806 shares under prior $50M facility.","Sales agents receive 3.0% commission on gross sales price; reimbursement capped at $125k setup, $35k execution, $54k for Q3 2024, and $15k per subsequent quarter.","ATM sales to be made on Nasdaq; settlement on first business day after sale; no escrow arrangement.","Company will report quarterly the number of shares sold and net proceeds from the program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176418,"accession_number":"0001641172-25-000922","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics FY2024 revenue $3.9M, net loss $37.6M; withdraws 510(k) for platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.9M vs $6.8M in 2023; product revenue $0.8M, grant revenue $3.1M.","Net loss $37.6M ($1.24/diluted share) vs $35.3M ($1.20) prior year.","Adjusted EBITDA loss of $33.5M; operating expenses $43.0M decreased 5.2% YoY.","Cash and marketable securities $29.7M as of Dec 31, 2024.","Withdrew initial 510(k) for Co-Dx PCR Pro; plans to resubmit enhanced version."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176417,"accession_number":"0001493152-25-007919","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Co-Diagnostics withdraws COVID-19 test 510(k) application; to submit enhanced version","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Withdrew current 510(k) application for Co-Dx PCR COVID-19 Test after FDA feedback on component shelf-life stability.","Plans to submit an enhanced version for OTC clearance after collecting new clinical evaluation data.","Enhanced version to incorporate recent PCR platform developments to improve manufacturing efficiencies.","Pipeline includes upcoming tests for tuberculosis, upper-respiratory multiplex, and HPV.","No specific timeline provided for the new submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176416,"accession_number":"0001493152-25-001705","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Co-Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice on Jan 10, 2025: closing bid price below $1.00 for 30 consecutive business days.","Compliance date July 9, 2025; must close at $1.00+ for ten consecutive business days.","Stock continues trading on Nasdaq Capital Market under symbol CODX.","If not compliant by July 9, may seek 180-day extension by meeting other listing standards and intending reverse split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193269,"accession_number":"0001493152-24-044279","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K/A","filed_at":"2024-11-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics board adopts annual Say-on-Pay votes after shareholder vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders at 2024 annual meeting voted majority in favor of annual advisory Say-on-Pay votes.","Board considered results and determined to hold annual Say-on-Pay votes until next frequency vote.","This 8-K/A amends original filing to disclose the board's frequency decision.","No other changes from original 8-K; meeting held August 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193270,"accession_number":"0001493152-24-044001","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.","Net loss $9.7M ($0.32 per diluted share) vs $6.0M ($0.20) prior year; operating loss $10.2M.","Adjusted EBITDA loss $8.8M; cash and securities $37.7M as of Sept 30, 2024.","FDA 510(k) review ongoing for Co-Dx PCR platform; TB, respiratory, HPV multiplex tests in pipeline.","India oligonucleotide (Co-Primers) mfg facility inauguration expected early Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":3765835.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209630,"accession_number":"0001493152-24-034599","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics shareholders elect James Nelson, approve executive compensation and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["James Nelson elected as director with 6,684,070 votes for and 4,008,945 withheld (4,376,742 broker non-votes).","Advisory vote on executive compensation passed with 9,312,471 for, 1,279,949 against, 100,595 abstain.","Shareholders chose a one-year frequency for future advisory votes on executive compensation (10,235,779 votes for 1 year).","Ratification of Tanner LLC as independent auditor for FY2024 approved with 13,285,933 for, 1,742,178 against, 41,646 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209629,"accession_number":"0001493152-24-030746","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.","Net loss of $7.6M ($0.25/share) improved from $8.9M ($0.31/share) YoY; adjusted EBITDA loss of $5.9M.","Operating loss of $7.7M compared to $12.0M in 2023; cash and securities of $44.9M as of June 30.","Submitted first 510(k) for Co-Dx PCR Pro platform with OTC COVID-19 test to FDA.","Opened new manufacturing facility in South Salt Lake for Co-Primers and PCR platform components."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":3124694.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227748,"accession_number":"0001493152-24-023796","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Co-Diagnostics files first FDA 510(k) for Co-Dx PCR Pro platform and OTC COVID-19 test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA receives 510(k) submission for Co-Dx PCR Pro instrument and OTC COVID-19 test.","Company plans to shortly pursue point-of-care (POC) clearance for the same test.","Other tests in pipeline include tuberculosis, HPV, strep A, and a respiratory multiplex (flu A/B, COVID-19, RSV).","CEO Dwight Egan says 510(k) clearance would validate the platform and enable commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227747,"accession_number":"0001493152-24-018418","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q1 net loss $9.3M ($0.31/share), revenue $0.5M, down 17% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.5M ($0.3M product, $0.2M grant) vs $0.6M in Q1 2023.","Operating loss $10.3M, net loss $9.3M, vs $10.0M and $5.8M prior year.","Adjusted EBITDA loss $8.4M, up from $7.2M; cash & securities $50.0M.","Appointed four new executives: President Richard Abbott, COO, CTO, CCO.","Opened new manufacturing facility in Salt Lake; plans 510(k) submission for PCR Pro and COVID-19 test."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":467854.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246550,"accession_number":"0001493152-24-010089","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Co-Diagnostics appoints Richard Abbott as President effective March 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Abbott, age 52, appointed President of Co-Diagnostics, effective March 15, 2024.","He previously served as President of Advanced Conceptions, a wholly owned subsidiary acquired in December 2021.","Through 50% ownership of Whiteknob LLC, he may earn up to 507,386 common shares and 166,503 warrants upon milestone achievements.","Holds MBA from Wharton and MS/BS in Mechanical Engineering from Brigham Young University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246549,"accession_number":"0001493152-24-009950","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics FY2023 revenue drops 80% to $6.8M; net loss widens to $35.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $6.8M, down from $34.2M in 2022, driven by decline in COVID-19 test demand.","Net loss of $35.3M ($1.20 per diluted share) vs. $14.2M ($0.45) in prior year.","Operating loss of $42.7M; adjusted EBITDA loss of $33.0M.","Submitted EUA to FDA for Co-Dx PCR Pro platform and COVID-19 test in December 2023.","Appointed Ivory Chang as Chief Regulatory Affairs Officer; secured $12.6M in grants for TB, respiratory, HPV tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263968,"accession_number":"0001493152-23-040049","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q3 revenue $2.5M, net loss $6.0M; receives $9.0M Gates Foundation grant","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.5M, down from $5.1M in prior year due to declining COVID-19 test demand.","Net loss of $6.0M ($0.20/sh) vs $1.4M loss ($0.04/sh) in prior year.","Received $9.0M grant from Bill & Melinda Gates Foundation for TB test development on Co-Dx PCR platform.","Expects EUA submission to FDA for Co-Dx PCR Pro platform and COVID-19 assay by year-end 2023.","Cash and securities $63.4M as of Sept 30, 2023; repurchased 149,041 shares at $1.12 avg."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":3256861.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281197,"accession_number":"0001493152-23-031051","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics shareholders elect directors, approve executive pay, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dwight Egan (6,103,488 for) and Eugene Durenard (4,017,019 for) as Class II directors for three-year terms.","Advisory vote on executive compensation approved: 6,426,011 for, 1,221,093 against, 236,466 abstain.","Ratified Tanner LLC as independent auditor for 2023: 14,966,948 for, 334,913 against, 393,098 abstain.","Broker non-votes were 7,811,389 on director election and executive compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281196,"accession_number":"0001493152-23-027534","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Revenue collapse to $0.2M, Q2 net loss $8.9M vs $2.7M a year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.2M vs $5.0M in prior-year quarter as COVID test demand declined.","Operating loss of $12.0M increased from $4.1M on pre-commercialization investments in Co-Dx PCR Home platform.","Net loss $8.9M ($0.31 per share loss) compared to $2.7M loss ($0.08 per share) a year ago.","Cash and securities $69.1M; repurchased 0.4M shares at avg $1.51 for ~$0.6M.","Received $1.2M NIH RADx grant and over $2.3M from Gates Foundation for TB/HPV test development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":799763.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299955,"accession_number":"0001493152-23-017799","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Co-Diagnostics adopts change-in-control severance plan; CEO 3x, CFO 2x multipliers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Change in Control Severance Plan for select management; CEO Dwight Egan gets 3x multiplier, CFO Brian Brown gets 2x.","Severance benefit = multiplier times (base salary + greater of target bonus or avg of three highest actual bonuses).","Benefits triggered by termination without cause or for good reason within 2 years after a change in control.","Payment is lump sum after signing separation agreement; subject to Section 409A limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299954,"accession_number":"0001493152-23-016376","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q1 revenue drops 97% to $0.6M; net loss of $5.8M vs prior-year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $0.6M, down from $22.7M a year ago due to lower COVID-19 test demand.","Net loss of $5.8M ($0.20 diluted EPS loss) vs net income of $11.7M ($0.34 EPS) in Q1 2022.","Operating loss of $10.0M vs operating income of $9.8M; adjusted EBITDA loss of $7.2M.","Cash, cash equivalents, and marketable securities of $75.3M as of March 31, 2023.","Co-Dx PCR Home platform clinical trials on track; FDA submission expected by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":601957.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299953,"accession_number":"0001493152-23-011062","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Co-Diagnostics appoints Tanner LLC as new auditor, replacing Haynie & Company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved engagement of Tanner LLC as independent auditor, effective upon filing of Q1 2023 10-Q.","Haynie & Company will be dismissed effective same date; their reports on FY2022 and FY2021 were unqualified.","No disagreements or reportable events with Haynie during fiscal years 2022, 2021, and interim period through March 31, 2023.","Company did not consult Tanner on accounting principles or audit opinions prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320048,"accession_number":"0001493152-23-007900","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics reports FY2022 revenue of $34.2M, down 65% YoY; net loss $0.45/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $34.2M, down from $97.9M in 2021 due to lower COVID-19 test demand.","Net loss $14.2M ($0.45 diluted EPS) vs net income $36.7M ($1.23) prior year.","Operating loss $27.0M, driven by lower revenue, goodwill impairment, R&D for Co-Dx PCR Home.","Adjusted net income (excl. goodwill) $1.2M, or $0.04 per diluted share.","Initiated clinical evaluations for Co-Dx PCR Home platform; cash $81.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338205,"accession_number":"0001493152-22-031335","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Co-Diagnostics Q3 revenue $5.1M (down 83% YoY); net loss $1.4M vs prior-year income $11.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.1M, down from $30.1M a year ago; operating loss $6.5M vs income $13.6M.","Net loss $1.4M ($0.04 loss per diluted share) vs net income $11.5M in Q3 2021.","Adjusted EBITDA loss $4.1M; cash, equivalents, and marketable securities $86.5M.","Repurchased 2.9M shares at avg $3.61; generated $1.1M operating cash flow in Q3.","Co-Dx PCR Home platform nearing clinical evaluations; shipped Monkeypox test and appointed new CSO Dr. Mark Poritz."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":32816726.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355575,"accession_number":"0001493152-22-024979","cik":1692415,"company_name":"Co-Diagnostics, Inc.","ticker":"CODX","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Co-Diagnostics shareholders approve 6M share increase for LTIP; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to increase share reserve under 2015 LTIP by 6,000,000 shares approved (7,646,908 for, 4,863,908 against).","Class I directors Edward L. Murphy and Richard S. Serbin re-elected with over 8.3M votes each.","Advisory vote on executive compensation passed: 11,540,967 for, 919,014 against.","Ratification of Haynie & Company as independent auditor for FY2022 passed: 20,879,301 for, 298,712 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":43878026.20273972,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-09-02T23:59:59+00:00|355575"}